Stryker
A global medical technology company supplying orthopedic implants, surgical equipment, neurotechnology products, and hospital-care systems.
Last updated October 19, 2026
AI crawler reads
3requests
1companies- Anthropic3
- Profile
- 2
- Controversies
- 1
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Stryker Corporation is an American multinational medical technology company headquartered in Portage, Michigan. Its products are used by hospitals, ambulatory surgery centers, emergency services, clinicians, and patients across orthopedic surgery, general and specialist surgery, neurotechnology, patient handling, intensive care, and healthcare safety. The company traces its origins to 1941, when orthopedic surgeon Homer Stryker established the Orthopedic Frame Company in Kalamazoo, Michigan. Stryker initially commercialized practical devices developed to solve clinical problems, including a mobile hospital bed that could reposition injured patients while maintaining body immobilization, a cast-removal saw, and a walking heel. The company adopted the Stryker Corporation name in 1964 and became publicly traded through an initial public offering in 1979. A major period of expansion followed under John W. Brown, who joined in 1977 and led the company as president and chief executive officer before becoming chairman. During his tenure, Stryker developed from a relatively small orthopedic-device manufacturer into a diversified medical technology enterprise. Stephen P. MacMillan became president and chief executive officer in 2003, and Kevin A. Lobo assumed the same roles in 2012 after a short interim leadership period. Stryker’s business is broadly organized around two major areas. Medical and surgical products include surgical equipment, endoscopy systems, patient and caregiver safety technologies, patient-handling equipment, emergency medical equipment, and disposable products for intensive care. Neurotechnology includes neurosurgical, neurovascular, and oral and maxillofacial surgery products. Orthopedics includes implants for total hip, knee, and shoulder replacement, as well as trauma and extremities products. The company also offers digitally enabled planning and robotic-assistance technologies, including the Mako system for orthopedic procedures. According to the cited 2024 business description, medical and surgical products together with neurotechnology represented approximately 60 percent of revenue, while orthopedics represented approximately 40 percent. The company reported that its products were sold in more than 75 countries and used in care involving approximately 150 million patients annually; the United States accounted for about 75 percent of 2024 revenue. Stryker’s positioning combines clinical workflow improvement, procedural precision, implant performance, hospital efficiency, and lifecycle support. Its commercial model depends on relationships with healthcare institutions and clinicians, regulatory approvals, specialized sales and service networks, and recurring demand for implants, capital equipment, disposables, and replacement components. The brand is associated particularly strongly with orthopedic reconstruction, trauma and extremities, surgical visualization, operating-room equipment, and robotic-assisted orthopedic surgery. Its history also includes regulatory scrutiny, product recalls, quality-system concerns, settlements involving marketing and foreign-corruption controls, and criticism of its continued commercial activity in Russia after the 2022 invasion of Ukraine. These events illustrate the regulatory and reputational risks inherent in medical-device manufacturing. Stryker remains an active, publicly listed medical technology company with a broad international portfolio.
History
Stryker's origins lie in the clinical practice of Homer Stryker, an orthopedic surgeon from Kalamazoo, Michigan. In 1941 he founded the Orthopedic Frame Company to manufacture devices addressing practical problems in patient care. Among the early products were the Turning Frame, a mobile hospital bed designed to reposition injured patients while preserving immobilization; a cast cutter intended to remove plaster without damaging underlying tissue; and the Walking Heel. This emphasis on products developed around specific clinical needs became a continuing feature of the company's identity. The business changed its name to Stryker Corporation in 1964. It later entered the public markets through an initial public offering in 1979, providing capital for product development, manufacturing, sales expansion, and acquisitions. John W. Brown joined the company in 1977 and became president and chief executive officer. He became chairman in 1981 and remained a central figure in the company's development until retiring as chairman in 2009. During his leadership, reported revenue increased from approximately $17 million to approximately $6.7 billion, reflecting Stryker's transformation from a small orthopedic manufacturer into a major medical technology company. Stephen P. MacMillan became president and chief executive officer in 2003. During the following decade Stryker continued broadening its portfolio beyond traditional orthopedic products into surgical equipment, endoscopy, patient handling, emergency care, and neurotechnology. In 2007 the company sold its Physiotherapy Associates division to Water Street Healthcare Partners. The same period brought significant regulatory pressure: FDA warning letters in 2007 and 2008 identified compliance, manufacturing, documentation, and quality-system issues at facilities in Ireland, New Jersey, and Massachusetts. Leadership changed again in 2012. MacMillan resigned, Curt R. Hartman served as interim chief executive officer while also holding senior finance responsibilities, and William U. Parfet became non-executive chairman. In October 2012, Kevin A. Lobo was appointed president and chief executive officer. Under the subsequent leadership structure, Stryker continued to operate as a diversified, globally distributed medical technology company with major businesses in orthopedics, surgical equipment, neurotechnology, and hospital-care technologies. The company's history has also included product-safety and compliance controversies. In 2012, Stryker recalled certain Neptune Waste Management System vacuum models after safety concerns involving use with drainage tubing. Hip products sold under the Rejuvenate and ABG II names became the subject of FDA action, product-related litigation, and substantial penalties and settlements described in public reporting. In 2013, Stryker resolved allegations concerning improper payments in several countries, and in 2018 it paid another penalty under the Foreign Corrupt Practices Act related to controls over sales practices in India, China, and Kuwait. In 2016, a Stryker subsidiary pursued a legal dispute in Europe concerning the classification of implant screws under EU procurement and customs nomenclature rules. Following Russia's 2022 invasion of Ukraine, external corporate-reputation assessments criticized Stryker for continuing ordinary business activity in Russia rather than substantially reducing or ending operations. In 2023, the company introduced the ProStep MIS Lapidus system for minimally invasive bunion treatment. By the period covered by the cited business description, Stryker sold products in more than 75 countries, with medical and surgical products plus neurotechnology accounting for about 60 percent of 2024 revenue and orthopedics accounting for about 40 percent. The company remains an active, publicly listed medical technology corporation.
- 2023
ProStep MIS Lapidus introduced
[1]Stryker launched a minimally invasive bunion-treatment system.
- 2012
Kevin A. Lobo appointed chief executive
[1]After an interim leadership period, Lobo became president and chief executive officer.
- 2007
Physiotherapy Associates divested
[1]Stryker sold its Physiotherapy Associates division to Water Street Healthcare Partners.
- 2003
Stephen P. MacMillan becomes chief executive
[1]MacMillan became president and chief executive officer.
- 1979
Initial public offering
[1]Stryker became a publicly traded company through an initial public offering.
- 1977
John W. Brown joins Stryker
[1]Brown joined the company as president and chief executive officer and later became chairman.
- 1964
Company renamed Stryker Corporation
[1]The business adopted the Stryker Corporation name.
- 1941
Orthopedic Frame Company founded
[1]Orthopedic surgeon Homer Stryker founded the original company in Kalamazoo, Michigan, to develop practical orthopedic and patient-care devices.
Products and positioning
A premium, innovation-led medical technology provider focused on improving surgical precision, clinical outcomes, hospital workflows, and patient and caregiver safety.
Robotic-assisted orthopedic surgery
Mako SmartRobotics
Mako is Stryker's robotic-assisted orthopedic surgery platform. It combines three-dimensional planning, patient-specific procedural preparation, and robotic assistance to support certain joint-replacement procedures. The platform is associated especially with hip and knee surgery and is intended to help surgeons execute a preoperative plan with greater consistency while retaining clinician control.
Knee replacement implants
Triathlon Knee System
The Triathlon family is a knee-replacement implant platform designed for total knee arthroplasty. It forms part of Stryker's orthopedic reconstruction portfolio and is supported by associated surgical instruments, planning tools, and clinical-use protocols. The system addresses the implant and instrumentation needs of hospitals and orthopedic surgeons performing knee replacement.
Foot and ankle surgery · 2023
ProStep MIS Lapidus System
Introduced in 2023, ProStep MIS Lapidus is a minimally invasive system for bunion correction. Its stated design goals include reducing recurrence and scarring while potentially lowering reliance on postoperative opioids. It extends Stryker's orthopedic offering into specialized foot and ankle procedures.
Surgical equipment
Neptune Waste Management System
Neptune is a surgical waste-management and fluid-evacuation product family used in operating-room environments. The system has been marketed as part of Stryker's surgical-equipment portfolio. Several models were recalled in 2012 following safety concerns involving the use of medical vacuums with drainage tubing.
Neurosurgical and neurovascular devices
Stryker Neurotechnology portfolio
Stryker's neurotechnology business includes products for neurosurgery, neurovascular intervention, and related cranial and oral and maxillofacial procedures. The portfolio complements the company's orthopedic and surgical-equipment businesses and includes implantable and procedural technologies used by specialist clinical teams.
Controversies
2019
Stryker announces a voluntary field action for certain LIFEPAK 15 units
Stryker announced a voluntary field action for specific LIFEPAK 15 monitor/defibrillator units after oxidation in the Shock button was found to potentially prevent delivery of a defibrillation shock. The company stated that it is contacting customers to arrange correction, including replacement of affected keypads. The announcement concerns only the identified units and describes the action as voluntary.
2019
Stryker launches corrective action for LIFEPAK 15 devices
Stryker announced a voluntary field action for specific LIFEPAK 15 monitor/defibrillators after an issue was identified that may prevent a device from delivering a shock when the "Shock" button is pressed. Stryker said it would contact affected customers to arrange correction, including replacement of the affected keypad.
2018
Foreign Corrupt Practices Act penalty
The company paid a penalty related to alleged failures to detect and prevent improper-payment risks in sales involving India, China, and Kuwait.
2013
Foreign-corruption settlement
Stryker resolved allegations that improper payments had been made in connection with sales activities in Argentina, Greece, Mexico, Poland, and Romania.
2012
Neptune Waste Management System recall
Several Neptune medical-vacuum models were recalled after a fatal accident and concerns that some devices lacked required FDA clearance.
2012
Rejuvenate and ABG II hip-system controversy
Stryker's Rejuvenate and ABG II hip-replacement systems became subject to FDA action, recall-related consequences, litigation, and penalties after reports that the devices could cause severe pain and other complications.
2008
FDA documentation and biotechnology-facility concerns
The FDA cited quality and compliance problems at a Massachusetts biotechnology facility, including issues involving product documentation. Stryker stated that employees involved in falsifying records had been terminated.
2007
FDA manufacturing and compliance warnings
FDA warning letters identified quality-system, manufacturing, testing, and corrective-action concerns at Stryker facilities in Ireland and New Jersey.
Brand decisions
2023
Launch ProStep MIS LapidusProduct launchBackground
Bunion surgery remains a specialized orthopedic and foot-and-ankle treatment area where minimally invasive techniques seek to reduce tissue disruption.
Action taken
Stryker introduced ProStep MIS Lapidus as a minimally invasive bunion-treatment system.
Aftermath
The launch broadened Stryker's specialized orthopedic offering, with stated aims including lower recurrence, less scarring, and reduced opioid use.
2012
Appoint Kevin A. Lobo as chief executiveOtherBackground
Stephen P. MacMillan resigned as chief executive officer in February 2012, followed by an interim period under Curt R. Hartman.
Action taken
Stryker appointed Kevin A. Lobo president and chief executive officer in October 2012.
Aftermath
Lobo led the company through its continued expansion as a diversified global medical technology business.
2007
Divest Physiotherapy AssociatesM&ABackground
Stryker reviewed the fit of its physiotherapy-services division within its medical-device portfolio.
Action taken
The division was sold to Water Street Healthcare Partners.
Aftermath
The divestiture concentrated Stryker more heavily on medical technology products and related healthcare equipment.
1979
Become a public companyStrategyBackground
Stryker needed a broader capital base to support product development and business expansion.
Action taken
The company completed an initial public offering.
Aftermath
Public-market access supported the company's subsequent development into a larger international medical technology company.
1964
Adopt the Stryker corporate nameStrategyBackground
The original Orthopedic Frame Company had developed around products associated with its founder's clinical inventions.
Action taken
The company changed its name to Stryker Corporation, establishing the founder's name as the central corporate brand.
Aftermath
The Stryker name subsequently became associated with a diversified medical technology portfolio rather than only orthopedic frames.
Recent events
Reported
Stryker completes acquisition of ZuriMED[5]
Stryker Corporation completed its acquisition of privately held ZuriMED, adding the FiberLocker System to Stryker’s Sports Medicine portfolio.
Reported
Stryker makes $400 million strategic investment in CMR Surgical[6]
Stryker announced on Monday (2026-10-12) that it has established a partnership with soft tissue robotics company CMR Surgical and made a strategic investment of about US$400 million (about NT$12.9 billion), marking Stryker's formal entry into soft tissue robotic surgery. The agreement also grants Stryker an exclusive option to acquire CMR Surgical's remaining shares in the future.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Reported
Stryker to become exclusive US distributor of CMR Surgical's Versius robot system[6]
Under the agreement announced on Monday (2026-10-12), Stryker will become the exclusive US distributor of CMR Surgical's Versius robotic system, while CMR Surgical continues to lead its commercial operations in other global markets.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Reported
Stryker announces agreement to acquire Vocera Communications[7]
Stryker announced a definitive agreement to acquire all issued and outstanding shares of Vocera Communications. The acquisition was expected to close in the first quarter of 2022.
Reported
Stryker launches 1688 4K dual-fluorescence imaging platform in China[8]
Stryker formally launched its 1688 4K dual-fluorescence intelligent imaging platform at the China International Import Expo; the article says it was making its domestic debut and would soon be introduced to hospitals nationwide.
Reported
Stryker launches Citrelock tendon fixation device system[9]
Stryker announced the launch of its Citrelock tendon fixation device system, an orthopedic device system featuring resorbable technology.
Reported
Stryker launches SurgiCount+ Safety-Sponge System[10]
Stryker announced the launch of SurgiCount+ Safety-Sponge System, its next-generation surgical sponge counting technology. The system enables healthcare providers to count and scan sponges and connect to hospital electronic medical records.
Reported
C2Dx acquires Stryker's T/Pump product line[11]
C2Dx acquired the T/Pump product line from Stryker.
Stryker launches corrective action for LIFEPAK 15 devices[4]
Stryker announced a voluntary field action for specific LIFEPAK 15 monitor/defibrillators after an issue was identified that may prevent a device from delivering a shock when the “Shock” button is pressed. Stryker said it would contact affected customers to arrange correction, including replacement of the affected keypad.
Reported
Stryker announces a voluntary field action for certain LIFEPAK 15 units[3]
Stryker announced a voluntary field action for specific LIFEPAK 15 monitor/defibrillator units after oxidation in the Shock button was found to potentially prevent delivery of a defibrillation shock. The company is contacting customers to arrange correction, including replacement of affected keypads.
Sources13 sources
- 1Stryker Corporationen.wikipedia.org
- 2Stryker official websitestryker.com
- 3Stryker announces a voluntary field action for certain LIFEPAK 15 unitsprnewswire.com
- 4Stryker launches corrective action for LIFEPAK 15 devicesfda.gov
- 5Stryker完成对ZuriMED的收购econotimes.com
- 6Stryker 斥资 4 亿美元策略性投资 CMR Surgicaln.yam.com
- 7Stryker宣布收购Vocera Communications的协议healio.com
- 8史赛克在中国发布1688 4K双荧光智能影像平台prnasia.com
- 9Stryker推出Citrelock肌腱固定装置系统healio.com
- 10Stryker推出SurgiCount+安全手术海绵系统prnewswire.com
- 11C2Dx 收购 Stryker 的 T/Pump 产品线prnewswire.com
- 12Stryker公布2019年第三季度业绩healio.com
- 13Kalamazooâs C2Dx Acquires T/Pump Product Line from Strykerdbusiness.com
Cite this profile: Cite the canonical profile. /brand-wiki/stryker · Editorial policy · How profiles are compiled